{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:23:10Z","timestamp":1790288590590,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bulcan.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T20:22:58Z","timestamp":1766521378000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimer le prix des cellules CAR-T en France\u00a0: du prix affich\u00e9 au prix r\u00e9el"],"prefix":"10.1016","volume":"113","author":[{"given":"Carole-Anne","family":"Brug\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Deschaseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Roffiaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9au","family":"Brigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.11.010_bib0125","first-page":"583","article-title":"\u00c9valuation des CAR-T cells par la Commission de la transparence de la Haute Autorit\u00e9 de sant\u00e9 (2018\u201323)","volume":"208","author":"Dahmani","year":"2024","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0130","first-page":"866","article-title":"Cellules humaines \u00e0 usage th\u00e9rapeutique\u00a0: \u00e9tat de la question","volume":"204","author":"Guilhot","year":"2020","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0135","unstructured":"Minist\u00e8re de la Sant\u00e9. ATU-AAP\u00a0: tableau des indemnit\u00e9s maximales (version du 15\/04\/2025) [en ligne]. 2025 [consult\u00e9 le 12\u00a0septembre 2025]. Disponible sur\u00a0: https:\/\/sante.gouv.fr\/IMG\/xlsx\/atu-aap_tableau_des_indemnites_maximales_version_du_15042025.xlsx."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0140","unstructured":"Cour des comptes. Rapport S\u00e9curit\u00e9 Sociale 2024\u00a0Chapitre IV Les m\u00e9dicaments anti-canc\u00e9reux\u00a0: mieux r\u00e9guler en pr\u00e9servant un acc\u00e8s rapide aux traitements innovants [en ligne]. 2024 [consult\u00e9 le 12\u00a0novembre 2025]. Disponible sur\u00a0: https:\/\/www.ccomptes.fr\/sites\/default\/files\/2024-05\/20240529-Ralfss-2024-Medicaments-anti-cancereux.pdf."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0145","unstructured":"Code de la S\u00e9curit\u00e9 Sociale. Articles L. 162-16-4\u00a0et L. 165-2. 2025."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0150","unstructured":"Cour des comptes. Note de synth\u00e8se\u00a0: l\u2019Objectif national de d\u00e9penses d\u2019assurance maladie (ONDAM): \u00e9volution, gouvernance et soutenabilit\u00e9 [en ligne]. 2025 [consult\u00e9 le 18\u00a0novembre 2025]. Disponible sur\u00a0: https:\/\/www.ccomptes.fr\/fr\/publications\/lobjectif-national-de-depenses-dassurance-maladie-ondam."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0155","unstructured":"Code de la S\u00e9curit\u00e9 Sociale. Articles L. 138-10. 2023."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0160","unstructured":"Accord-cadre entre le Comit\u00e9 \u00e9conomique des produits de sant\u00e9 (CEPS) et les entreprises du m\u00e9dicament (LEEM), 2021\u20132024."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0165","first-page":"590","article-title":"Les cellules CAR-T\u00a0: prix, efficience et soutenabilit\u00e9 en France","volume":"208","author":"de Pouvourville","year":"2024","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0170","first-page":"9","article-title":"Rapport 23-22. M\u00e9dicaments anticanc\u00e9reux on\u00e9reux\u00a0: disponibilit\u00e9 et soutenabilit\u00e9 \u00e9conomique","volume":"208","author":"Guilhot","year":"2024","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0175","series-title":"Pricing of cancer medicines and its impacts","year":"2018"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0180","series-title":"La cellule, l\u2019industrie et l\u2019h\u00f4pital\u00a0: le syst\u00e8me de sant\u00e9 fran\u00e7ais face \u00e0 la promesse CAR-T. Th\u00e8se de Doctorat en sant\u00e9 et sciences sociales, sous la direction de Maurice Cassier, Emmanuel Didier","author":"Brigand","year":"2024"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0185","unstructured":"S\u00e9nat. R\u00e9ponse du minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention publi\u00e9e dans le JO S\u00e9nat du 22\/06\/2023 - page 3937 [en ligne]. 2023 [consult\u00e9 le 12\u00a0septembre 2025]. Disponible sur\u00a0: https:\/\/www.senat.fr\/questions\/base\/2023\/qSEQ230406277.html."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0190","series-title":"Avis de la Commission de la transparence le 16\u00a0juillet 2025\u00a0sur CARVYKTI","year":"2025"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0195","series-title":"Rapport d\u2019activit\u00e9 2023","year":"2023"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0200","series-title":"Rapport d\u2019activit\u00e9 2018","year":"2018"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0205","series-title":"Rapport d\u2019activit\u00e9 2022","year":"2022"},{"issue":"12\u00a0Suppl","key":"10.1016\/j.bulcan.2025.11.010_bib0210","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1016\/j.jval.2024.10.2187","article-title":"HTA362\u00a0\u2013\u00a0The cost of innovation: evaluating the evolution of willingness-to-pay for CAR-T therapies in Germany","volume":"27","author":"Cullen","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0215","unstructured":"Lauer Taxe online. Base officielle des prix pharmaceutiques en Allemagne. 2025 [consult\u00e9 le 18\u00a0novembre 2025]."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0220","unstructured":"Bot PLUS Web. Base de donn\u00e9es du Conseil g\u00e9n\u00e9ral des coll\u00e8ges pharmaceutiques d\u2019Espagne. 2025 [consult\u00e9 le 18\u00a0novembre 2025]."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0225","unstructured":"Gazzetta Ufficiale. Journal officiel de la R\u00e9publique italienne. 2025 [consult\u00e9 le 18\u00a0novembre 2025]."},{"key":"10.1016\/j.bulcan.2025.11.010_bib0230","series-title":"Exploring the feasibility of sharing information on medicine prices across countries. OECD Health Working Papers No. 171","author":"Moens","year":"2024"},{"key":"10.1016\/j.bulcan.2025.11.010_bib0235","series-title":"Ex-manufacturer price history report","year":"2025"},{"issue":"10","key":"10.1016\/j.bulcan.2025.11.010_bib0120","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.bulcan.2021.07.002","article-title":"DESCAR-T, le registre national des patients trait\u00e9s par CAR-T cells","volume":"108","author":"Broussais","year":"2021","journal-title":"Bull Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:14:24Z","timestamp":1768814064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125005338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0007455125005338"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimer le prix des cellules CAR-T en France\u00a0: du prix affich\u00e9 au prix r\u00e9el","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}